Breaking News Instant updates and real-time market news.

HBM

Hudbay Minerals

$4.93

-0.1 (-1.99%)

, ESTA

Establishment Labs

$27.10

(0.00%)

10:16
08/14/18
08/14
10:16
08/14/18
10:16

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Hudbay Minerals (HBM) reinstated with a Neutral at BofA/Merrill. 2. Establishment Labs (ESTA) initiated with a Buy at BTIG and Jefferies and an Outperform at Cowen. 3. Yext (YEXT) initiated with a Buy at SunTrust. 4. Akebia (AKBA) initiated with an Outperform at Raymond James. 5. Replimune Group (REPL) was initiated with an Outperform at Leerink and BMO Capital as well as an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

HBM

Hudbay Minerals

$4.93

-0.1 (-1.99%)

ESTA

Establishment Labs

$27.10

(0.00%)

YEXT

Yext

$22.84

0.27 (1.20%)

AKBA

Akebia

$8.22

0.4 (5.12%)

REPL

Replimune Group

$17.10

0.01 (0.06%)

  • 14

    Aug

  • 16

    Aug

HBM Hudbay Minerals
$4.93

-0.1 (-1.99%)

08/14/18
BOFA
08/14/18
INITIATION
Target $6
BOFA
Neutral
Hudbay Minerals reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Lawson Winder reinstated Hudbay Minerals with a Neutral and $6 price target to reflect the ongoing uncertainty around the Rosemont project and declining production.
04/02/18
ADAM
04/02/18
UPGRADE
ADAM
Buy
Hudbay Minerals upgraded to Buy from Hold at Canaccord
04/17/18
TDSI
04/17/18
DOWNGRADE
TDSI
Buy
Hudbay Minerals downgraded to Buy from Action List Buy at TD Securities
06/25/18
SCOT
06/25/18
DOWNGRADE
SCOT
Outperform
Hudbay Minerals downgraded to Outperform from Focus List at Scotiabank
ESTA Establishment Labs
$27.10

(0.00%)

08/13/18
COWN
08/13/18
INITIATION
COWN
Outperform
Establishment Labs initiated with an Outperform at Cowen
08/13/18
JEFF
08/13/18
INITIATION
Target $35
JEFF
Buy
Jefferies starts Establishment Labs with Buy rating, $35 target
Jefferies analyst Raj Denhoy initiated coverage of Establishment Labs with a Buy rating and $35 price target. With its Motiva implant, the company has "reimagined breast augmentation," Denhoy tells investors in a research note. The analyst models for annual revenue growth of 30% over the next five years. However, should the clinical data continue to be as good as the early results, the opportunity for Establishment Labs "to grow well beyond that is significant," Denhoy contends.
08/13/18
BTIG
08/13/18
INITIATION
Target $35
BTIG
Buy
Establishment Labs initiated with a Buy at BTIG
BTIG analyst Sean Lavin initiated Establishment Labs with a Buy rating and a price target of $35, saying he expects the company's Motiva portfolio to be a "channel disruptor" in the breast implant market given its "natural feel and impressive safety profile". The analyst expects Establishment Labs' "continued geographic expansion and momentum in Brazil" to produce above-average revenue growth in the near-term, while noting that the company's biggest risks are "competition and sustainability of exceptional outcomes".
08/13/18
JEFF
08/13/18
INITIATION
Target $35
JEFF
Buy
Establishment Labs initiated with a Buy at Jefferies
Jefferies started Establishment Labs Holdings with a Buy rating and $35 price target saying the company has a better breast impact in a market "ripe for innovation."
YEXT Yext
$22.84

0.27 (1.20%)

07/11/18
KEYB
07/11/18
DOWNGRADE
KEYB
Sector Weight
Yext downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Brent Bracelin downgraded Yext to Sector Weight saying shares are approaching $20 fair value following a 62% run year-to-date.
08/13/18
RHCO
08/13/18
INITIATION
Target $27
RHCO
Buy
Yext initiated with a Buy at SunTrust
SunTrust analyst Naved Khan initiated Yext with a Buy and $27 price target.
07/11/18
07/11/18
DOWNGRADE

Sector Weight
Yext downgraded to Sector Weight on balanced risk/reward at KeyBanc
As previously reported, KeyBanc analyst Brent Bracelin downgraded Yext to Sector Weight from Overweight based on a risk/reward profile that now appears balanced in the short run, with a fair value estimate of $20 after shares have risen 62% year to date versus 12% for the Nasdaq Composite.
08/14/18
RHCO
08/14/18
INITIATION
Target $27
RHCO
Buy
Yext initiated with a Buy at SunTrust
As reported earlier, SunTrust analyst Naved Khan initiated Yext with a Buy rating and a price target of $27. The analyst notes that the company is a leader in the Digital Knowledge Management category with estimated total addressable market of over $10B. Khan adds that its large product network, growing customer base, and product innovation combined offer a "competitive moat", while the company also stands to benefit from increasing web use in the search and management of business information.
AKBA Akebia
$8.22

0.4 (5.12%)

07/12/18
PIPR
07/12/18
NO CHANGE
Target $22
PIPR
Overweight
Piper incrementally positive on Akebia shares, ups target to $22
Piper Jaffray analyst Christopher Raymond is incrementally positive on shares of Akebia Therapeutics after new nephrologist survey data indicated that Auryxia "has not just turned a corner, but is really on quite a roll, both in terms of the drug's perception and its market share dynamics." With the stock down 4% since before last month's merger announcement with Keryx (KERX), Raymond sees a "significant opportunity" to own Akebia before the drug's near-term share gains and the "real potential of a nephrology powerhouse with both Auryxia and vadadustat, become more apparent." He raised his price target for the shares to $22 from $20 and keeps an Overweight rating on the name.
06/28/18
PIPR
06/28/18
NO CHANGE
Target $20
PIPR
Overweight
Akebia tie-up with Keryx makes good long-term sense, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond urges patience despite today's negative reaction to Akebia's (AKBA) merger of equals with Keryx (KERX) as he thinks the combination to create a fully integrated, renal-focused pharma company makes good strategic sense over the long-term and he believes the deal will be received much better by clinicians and other stakeholders than it has been so far by investors. The announcement was also complicated by the coincident disclosure of a delay to vadadustat's data, but Raymond does not think it detracts from the probability of success for the drug. He lowered his price target on Akebia shares to $20 from $23 and keeps an Overweight rating on the stock, which is down 10% to $9.28 in afternoon trading.
08/13/18
RAJA
08/13/18
INITIATION
Target $18
RAJA
Outperform
Akebia initiated with an Outperform at Raymond James
Raymond James analyst Reni Benjamin initiated Akebia (AKBA) with an Outperform and $18 price target saying the company is developing a novel therapy, vadadustat, for chronic kidney disease associated anemia, representing an almost $10B market opportunity. Benjamin recommends shares due to positive clinical data generated by vadadustat and other agents of the same class, Phase III trial read-outs expected over the next 12-24 months, several multi-national pharma partnerships, and the pending merger with Keryx Biopharmaceuticals (KERX).
07/03/18
MZHO
07/03/18
NO CHANGE
Target $21
MZHO
Buy
Akebia merger with Keryx strategically positive, says Mizuho
Mizuho analyst Difei Yang likes Akebia Therapeutics' (AKBA) merger with Keryx Biopharmaceuticals (KERX) from a "strategic and financial standpoint over time." The companies' products are complementary and will provide multiple avenues of value creation for the "new" Akebia, Yang tells investors in a research note. The analyst lowered his price target for Akebia to $21 from $24 and keeps a Buy rating on the shares.
REPL Replimune Group
$17.10

0.01 (0.06%)

08/14/18
LEER
08/14/18
INITIATION
Target $25
LEER
Outperform
Replimune Group initiated with an Outperform at Leerink
Leerink analyst Jonathan Chang started Replimune Group with an Outperform rating and $25 price target. While the company is still in the early stages of clinical development, the analyst has a positive long-term view on the stock because of Replimune Group's experienced management team, clear clinical strategy moving into combination trials, and potential broad applicability to injectable tumors. Chang also believes that it has a lower risk profile when compared to other oncolytic virus companies.
08/14/18
JPMS
08/14/18
INITIATION
Target $26
JPMS
Overweight
Replimune Group initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama started Replimune Group with an Overweight rating and $26 price target. Replimune is an emerging oncolytic immunotherapy platform company that has "multiple de-risking points," Rama tells investors in a research note.
08/14/18
BMOC
08/14/18
INITIATION
Target $31
BMOC
Outperform
Replimune Group initiated with an Outperform at BMO Capital
08/14/18
BMOC
08/14/18
INITIATION
Target $31
BMOC
Outperform
Replimune Group initiated with an Outperform at BMO Capital
As reported earlier, BMO Capital analyst Do Kim initiated Replimune with an Outperform rating and a price target of $31, saying its platform has been "significantly de-risked" based on its "structural similarity to T-Vec, the only FDA-approved oncolytic virus." The analyst contends that Replimune's RP1 is better than T-Vec, with a " more potent HSV-1 strain and addition of fusogenic protein GALV", and can deliver on rising expectations for oncolytic viruses helped by the advent of immunotherapy.

TODAY'S FREE FLY STORIES

LOB

Live Oak Bancshares

$13.67

-2.98 (-17.90%)

07:47
12/12/18
12/12
07:47
12/12/18
07:47
Upgrade
Live Oak Bancshares rating change  »

Live Oak Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$189.58

-3.36 (-1.74%)

07:47
12/12/18
12/12
07:47
12/12/18
07:47
Recommendations
FedEx analyst commentary  »

FedEx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

VST

Vistra Energy

$23.92

0.28 (1.18%)

07:45
12/12/18
12/12
07:45
12/12/18
07:45
Recommendations
Vistra Energy analyst commentary  »

Vistra Energy shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABIL

Ability

$2.37

0.005 (0.21%)

07:45
12/12/18
12/12
07:45
12/12/18
07:45
Hot Stocks
Ability regains Nasdaq compliance »

Ability announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARRY

Array BioPharma

$15.45

0.02 (0.13%)

07:44
12/12/18
12/12
07:44
12/12/18
07:44
Recommendations
Array BioPharma analyst commentary  »

Array BioPharma price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$18.02

0.02 (0.11%)

07:44
12/12/18
12/12
07:44
12/12/18
07:44
Initiation
iQIYI initiated  »

iQIYI initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THS

TreeHouse

$51.64

2.69 (5.50%)

07:43
12/12/18
12/12
07:43
12/12/18
07:43
Recommendations
TreeHouse analyst commentary  »

TreeHouse price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMPH

KemPharm

$2.78

0.07 (2.58%)

07:43
12/12/18
12/12
07:43
12/12/18
07:43
Hot Stocks
KemPharm presents research on IV abuse potential of SDX at ACNP »

KemPharm announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCCO

Southern Copper

$32.17

-0.08 (-0.25%)

07:43
12/12/18
12/12
07:43
12/12/18
07:43
Downgrade
Southern Copper rating change  »

Southern Copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THS

TreeHouse

$51.64

2.69 (5.50%)

07:43
12/12/18
12/12
07:43
12/12/18
07:43
Recommendations
TreeHouse analyst commentary  »

TreeHouse price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASR

Asur

$141.69

-0.66 (-0.46%)

07:42
12/12/18
12/12
07:42
12/12/18
07:42
Upgrade
Asur rating change  »

Asur upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$142.07

0.2 (0.14%)

, GOOGL

Alphabet Class A

$1,061.32

8.52 (0.81%)

07:42
12/12/18
12/12
07:42
12/12/18
07:42
Recommendations
Facebook, Alphabet Class A analyst commentary  »

Facebook testing search…

FB

Facebook

$142.07

0.2 (0.14%)

GOOGL

Alphabet Class A

$1,061.32

8.52 (0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSTM

Constellium

$8.12

0.2 (2.53%)

07:40
12/12/18
12/12
07:40
12/12/18
07:40
Conference/Events
Constellium to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 17

    Dec

  • 18

    Dec

ZLAB

Zai Lab

$19.93

-0.01 (-0.05%)

07:39
12/12/18
12/12
07:39
12/12/18
07:39
Hot Stocks
Zai Lab announces acceptance of Zejula NDA submission by NMPA »

Zai Lab announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDGL

Madrigal Pharmaceuticals

$114.69

1.8 (1.59%)

07:39
12/12/18
12/12
07:39
12/12/18
07:39
Recommendations
Madrigal Pharmaceuticals analyst commentary  »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHAK

Shake Shack

$46.73

-0.85 (-1.79%)

07:38
12/12/18
12/12
07:38
12/12/18
07:38
Recommendations
Shake Shack analyst commentary  »

Shake Shack price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

AEO

American Eagle

$19.03

-0.49 (-2.51%)

07:36
12/12/18
12/12
07:36
12/12/18
07:36
Recommendations
American Eagle analyst commentary  »

American Eagle shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAR

Marriott

$110.04

-0.78 (-0.70%)

07:36
12/12/18
12/12
07:36
12/12/18
07:36
Downgrade
Marriott rating change  »

Marriott downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYND

MYnd Analytics

$1.26

-0.04 (-3.08%)

07:35
12/12/18
12/12
07:35
12/12/18
07:35
Hot Stocks
MYnd Analytics appoints Patrick Herguth CEO, George Carpenter CIO »

MYnd Analytics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$24.58

-0.17 (-0.69%)

, T

AT&T

$29.70

-0.21 (-0.70%)

07:35
12/12/18
12/12
07:35
12/12/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

BAC

Bank of America

$24.58

-0.17 (-0.69%)

T

AT&T

$29.70

-0.21 (-0.70%)

NIO

NIO Inc.

$7.05

0.03 (0.43%)

BX

Blackstone

$30.50

0.03 (0.10%)

KHC

Kraft Heinz

$48.38

0.1 (0.21%)

NBR

Nabors Industries

$2.82

0.12 (4.44%)

KKR

KKR

$20.92

-0.21 (-0.99%)

TROX

Tronox

$7.11

0.06 (0.85%)

MLCO

Melco Resorts & Entertainment

$17.36

0.35 (2.06%)

DLPH

Delphi Technologies

$16.07

0.26 (1.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 18

    Dec

  • 30

    Jan

  • 12

    Feb

  • 20

    Mar

07:35
12/12/18
12/12
07:35
12/12/18
07:35
General news
U.S. MBA mortgage market index rose 1.6% »

U.S. MBA mortgage market…

AUDVF

Audi AG

$0.00

(0.00%)

07:34
12/12/18
12/12
07:34
12/12/18
07:34
Hot Stocks
Audi names interim CEO Bram Schot as chairman of the board »

The Supervisory Board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTB

Cooper Tire

$30.71

0.12 (0.39%)

07:34
12/12/18
12/12
07:34
12/12/18
07:34
Hot Stocks
Cooper Tire, Sailun announce JV for new TBR tire plant in Vietnam »

Cooper Tire & Rubber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARDS

Aridis Pharmaceuticals

$7.96

0.02 (0.25%)

07:32
12/12/18
12/12
07:32
12/12/18
07:32
Hot Stocks
Aridis Pharmaceuticals enrolls first subject in Phase 1/2a lung infection trial »

Aridis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBIX

Neurocrine

$85.72

-0.14 (-0.16%)

07:32
12/12/18
12/12
07:32
12/12/18
07:32
Hot Stocks
Neurocrine says valbenazine did not meet primary endpoint in Phase IIb study »

Neurocrine Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.